Stahl's Essential Psychopharmacology Online
In Collaboration With
Index
The 
-icon indicates content; the 
-icon indicates figures; the 
-icon indicates tables.
- l-alpha-acetylmethodol acetate (LAAM),
- L channel, ,
- la-do (lamotrigine-Depakote), ,
- la-li-do (lamotrigine-lithium-Depakote), ,
- la-li (lamotrigine-lithium), ,
- lactation,
- Lami-quel, ,
- lamotrigine,
- actions as mood stabilizer,
- binding site of,
- for bipolar disorder,
- with depression,
- combination of medications with, ,
- and glutamate reduction,
- icon,
- mechanism of action
- on GABA, glutamate, sigma, and dopamine,
- VSSCs, synaptic vesicles, and carbonic anhydrase,
- putative clinical actions,
- rashes from,
- for schizophrenia,
- adding to antipsychotic,
- sites of action, on glutamate release,
- and VSSCs,
- language, odd use of,
- late gene,
- lateral fissure,
- lateral parabrachial nucleus,
- lazaroids, as free radical scavenger,
- learning
- and brain restructuring,
- constant synaptic revision and,
- and endogenous growth factors,
- gene expression and,
- long-term,
- and neurogenesis in hippocampus, ,
- learning disabilities, from improper neuronal migration,
- learning model, and circuit inefficiency,
- lecozotan,
- leptin,
- leucine zipper transcription factor, , , , ,
- Leucovorin (folinic acid),
- levetiracetam, ,
- icon,
- mechanism of action
- on GABA, glutamate, sigma, and dopamine,
- at SV2A symaptic vesicle sites,
- VSSCs, synaptic vesicles, and carbonic anhydrase,
- putative clinical actions,
- and seizure reduction,
- levodopa, for Parkinson’s disease, MAO-B inhibition and,
- Lewy bodies
- damage to cholinergic neurons,
- dementia with,
- li-do (lithium-Depakote/divalproex/valproate), ,
- libido, decreased,
- licarbazepine,
- binding site of,
- mechanism of action
- on GABA, glutamate, sigma, and dopamine,
- VSSCs, synaptic vesicles, and carbonic anhydrase,
- oxcarbazepine conversion to,
- putative clinical actions,
- lidocaine
- anatomic site of action,
- molecular site of action,
- and VSSC block,
- life cycle, antidepressants over, ,
- life expectancy, of schizophrenic patients,
- lifestyle, and stress,
- ligand-gated ion channels, , ,
- agonists impact on,
- different states,
- GABA receptors as,
- pentameric subtypes,
- as psychotropic drug target,
- states,
- structure and function, ,
- subunit of tetrameric,
- top view,
- tetrameric structure,
- limbic cortex, noradrenergic receptor simulation in,
- limbic CSTC circuit,
- lipid neurotransmitter,
- lithium, ,
- for affective symptoms in schizophrenia,
- for Alzheimer’s disease,
- for bipolar disorder,
- in combos
- for bipolar disorder,
- for depression,
- for depression,
- in bipolar disorder,
- for dopamine hyperactivity reduction,
- and fetal toxicity risk,
- GSK-3 inhibition by,
- mechanism of action,
- as mood stabilizer,
- side effects of,
- for suicide reduction, ,
- liver
- CYP450 enzymes in,
- insulin resistance in, ,
- riluzole impact
- valproic acid toxicity,
- local anesthesia, ,
- and VSSC block,
- locus coeruleus (LC),
- connection with amygdala,
- excessive noradrenergic output from,
- lofepramine (Deprimyl, Gamanil),
- long-term outcomes, symptom exacerbation and,
- long-term potentiation (LTP), , ,
- Loroxyl (amitriptyline, Elavil, Endep, Tryptizol), , ,
- Lou Gehrig’s disease. See amyotrophic lateral sclerosis (ALS)
- lovastatin
- and CYP 450 3A4,
- risk of muscle damage,
- low-potency antipsychotic agents, and dissociation,
- loxapine (Loxitane),
- 5HT6-antagonist properties of,
- pharmacological icon,
- Loxitane. See loxapine (Loxitane)
- LSD (d-lysergic acid diethylamide),
- actions,
- LTP. See long-term potentiation (LTP)
- LuAA34893, ,
- Ludiomil (maprotiline),
- inhibition of serotonin reuptake pump,
- luxapine,
- LY 293558,
- LY354740,
- LY379268,
- LY450139,
- d-lysergic acid diethylamide (LSD),
- actions,
- lysosomes, ,
- localization of,
- organelle and protein destruction by, ,